Compare BRCB & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | BNR |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | China |
| Employees | 2800 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.8M | 179.7M |
| IPO Year | N/A | 2019 |
| Metric | BRCB | BNR |
|---|---|---|
| Price | $6.87 | $8.93 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $24.83 | N/A |
| AVG Volume (30 Days) | ★ 900.6K | 12.8K |
| Earning Date | 05-12-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.74 | $111.65 |
| Revenue Next Year | $24.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.13 | $2.88 |
| 52 Week High | $30.40 | $41.72 |
| Indicator | BRCB | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 30.72 | 24.38 |
| Support Level | $6.13 | $7.99 |
| Resistance Level | $17.60 | $9.70 |
| Average True Range (ATR) | 0.66 | 1.33 |
| MACD | 0.15 | -0.70 |
| Stochastic Oscillator | 25.09 | 4.91 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.